PCM
AVDL

Penn Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Penn Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-608,399
Closed -$8M – 148
2024
Q3 		$8M Buy
+608,399
New +$9.27M 0.73% 65
2024
Q2 		– Sell
-686,606
Closed -$11.6M – 150
2024
Q1 		$11.6M Buy
+686,606
New +$10.2M 1.03% 48
2015
Q4 		– Sell
-81,163
Closed -$1.32M – 262
2015
Q3 		$1.32M Sell
81,163
-36,159
-31% -$796K 0.07% 238
2015
Q2 		$2.49M Sell
117,322
-169,593
-59% -$3.04M 0.1% 219
2015
Q1 		$5.16M Buy
286,915
+82,618
+40% +$1.29M 0.2% 162
2014
Q4 		$3.5M Buy
+204,297
New +$2.92M 0.15% 196

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Penn Capital Management's AVDL Position: Q4 2024 in Review

Penn Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 608,399 shares — an estimated $8M sold.

Penn Capital Management first reported a position in AVDL in Q4 2014 and held it in 6 quarters. The position peaked at $11.6M in Q1 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

  • Penn Capital Management reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Penn Capital Management sold 608,399 Avadel Pharmaceuticals shares in Q4 2024, an estimated $8M.
  • Penn Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 6 quarters.
  • Penn Capital Management's Avadel Pharmaceuticals position peaked at $11.6M in Q1 2024.
  • 159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Penn Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.